Abstract library

4 results for "Exner".
#1506 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells
Introduction: PRRT can deliver radiation doses of up to 250 Gy to the tumors. Nevertheless, complete remission is extremely rare, compared to similar radiotherapies for thyroid cancer and non-Hodgkin lymphoma.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Carsten Grötzinger
Keywords: PRRT
#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents
Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Franziska Briest
#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells
Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger
Keywords: PRRT
#2294 Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors
Introduction: Neuroendocrine tumours (NETs) have been found to overexpress somatostatin receptors (SSTRs), which led to the development of somatostatin analogs utilized for diagnostics and therapeutics. However, around 30% of all NETs do not respond to somatostatin based approaches, leading to an interest to find and characterize alternative cell surface targets.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger